Animal studies revealed that SCD1 deficiency leads to improvement of insulin sensitivity, decreased lipogenesis, and increases FA oxidation in the liver, which protect the animals from diet-induced obesity and hepatic insulin resistance [55,56,57] As mentioned above, NAFLD patients display elevated ratios of 16:1 n7/16:0 and 18:1 n9/18:0 [21,26,30], which suggests increased liver SCD1 activity. Here, SCD is linked to metabolic dysfunction-associated steatotic liver disease.